The Globe and Mail28m
Stocks Settle Lower on Weakness in Chip Stocks
Bristol Myers Squibb (BMY) closed up more than +1% after gaining FDA approval for its Cobenfy drug to treat patients with schizophrenia. Amgen (AMGN) closed up more than +1% after Cantor Fitzgerald ...
Boise State Public Radio40m
A new kind of drug for schizophrenia promises fewer side effects
A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...
The Globe and Mail58m
Dow Jones Climbs to New Record Highs, While the Nasdaq Slides
Bristol Myers Squibb (BMY) is up more than +1% after gaining FDA approval for its Cobenfy drug to treat patients with schizophrenia. Amgen (AMGN) is up more than +1% after Cantor Fitzgerald initiated ...
Dow closes at record high as tame inflation report also lifts small caps
The blue-chip Dow Jones Industrial Average closed at a record high as a subdued inflation report stoked hopes for more ...